In the last weeks, the consumption of Doliprane has doubled. This paracetamol medication is the main treatment for those who develop a mild form of Covid-19.
Faced with rising demand and to avoid a possible shortage, the Sanofi plant in Compiègne increased its production rates.
(Source: TF1)

